The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma

Overview

Journal JTO Clin Res Rep

Date 2022 May 5

PMID 35510132

Authors

Paul Wheatley-Price

Sara Moore

Christopher W Lee

Affiliations

Soon will be listed here.

References

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View

Nowak A, Lesterhuis W, Kok P, Brown C, Hughes B, Karikios D . Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020; 21(9):1213-1223. DOI: 10.1016/S1470-2045(20)30462-9. View

Facile R, Muhlbradt E, Gong M, Li Q, Popat V, Petavy F . Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey. JMIR Med Inform. 2022; 10(1):e30363. PMC: 8832264. DOI: 10.2196/30363. View

Di Maio M, Perrone F, Conte P . Real-World Evidence in Oncology: Opportunities and Limitations. Oncologist. 2019; 25(5):e746-e752. PMC: 7216461. DOI: 10.1634/theoncologist.2019-0647. View

Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W . A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep. 2022; 3(3):100280. PMC: 8861643. DOI: 10.1016/j.jtocrr.2022.100280. View

Kindler H, Ismaila N, Armato 3rd S, Bueno R, Hesdorffer M, Jahan T . Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(13):1343-1373. PMC: 8058628. DOI: 10.1200/JCO.2017.76.6394. View

Stang P, Ryan P, Racoosin J, Overhage J, Hartzema A, Reich C . Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010; 153(9):600-6. DOI: 10.7326/0003-4819-153-9-201011020-00010. View

Fennell D, Ewings S, Ottensmeier C, Califano R, Hanna G, Hill K . Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021; 22(11):1530-1540. PMC: 8560642. DOI: 10.1016/S1470-2045(21)00471-X. View

10.

Osterman T, Terry M, Miller R . Improving Cancer Data Interoperability: The Promise of the Minimal Common Oncology Data Elements (mCODE) Initiative. JCO Clin Cancer Inform. 2020; 4:993-1001. PMC: 7713551. DOI: 10.1200/CCI.20.00059. View

11.

Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan M . First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022; 33(5):488-499. DOI: 10.1016/j.annonc.2022.01.074. View

12.

Tsao A, Nakano T, Nowak A, Popat S, Scagliotti G, Heymach J . Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Semin Oncol. 2019; 46(2):145-154. DOI: 10.1053/j.seminoncol.2019.06.001. View